6BG logo

Lytix Biopharma DB:6BG Stock Report

Last Price

€0.68

Market Cap

€32.0m

7D

32.6%

1Y

39.6%

Updated

03 Dec, 2024

Data

Company Financials +

6BG Stock Overview

A, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. More details

6BG fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Lytix Biopharma AS Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Lytix Biopharma
Historical stock prices
Current Share PriceNOK 0.68
52 Week HighNOK 1.04
52 Week LowNOK 0.41
Beta-0.67
11 Month Change16.33%
3 Month Change-11.86%
1 Year Change39.59%
33 Year Change-49.11%
5 Year Changen/a
Change since IPO-56.60%

Recent News & Updates

Recent updates

Shareholder Returns

6BGDE BiotechsDE Market
7D32.6%1.9%1.5%
1Y39.6%-15.1%8.8%

Return vs Industry: 6BG exceeded the German Biotechs industry which returned -15.1% over the past year.

Return vs Market: 6BG exceeded the German Market which returned 8.8% over the past year.

Price Volatility

Is 6BG's price volatile compared to industry and market?
6BG volatility
6BG Average Weekly Movement11.3%
Biotechs Industry Average Movement6.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.9%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 6BG's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 6BG's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2003n/aOystein Rekdalwww.lytixbiopharma.com

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company’s products comprise of LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase.

Lytix Biopharma AS Fundamentals Summary

How do Lytix Biopharma's earnings and revenue compare to its market cap?
6BG fundamental statistics
Market cap€31.99m
Earnings (TTM)-€6.96m
Revenue (TTM)€924.84k

34.6x

P/S Ratio

-4.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6BG income statement (TTM)
RevenueNOK 10.76m
Cost of RevenueNOK 0
Gross ProfitNOK 10.76m
Other ExpensesNOK 91.68m
Earnings-NOK 80.92m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.63
Gross Margin100.00%
Net Profit Margin-752.26%
Debt/Equity Ratio0%

How did 6BG perform over the long term?

See historical performance and comparison